Results 131 to 140 of about 5,434 (169)

Tumor Intrinsic and Extrinsic Immune Functions of CD155

Seminars in Cancer Biology, 2020
CD155 (PVR/necl5/Tage4), a member of the nectin-like family of adhesion molecules, is highly upregulated on tumor cells across multiple cancer types and has been associated with worse patient outcomes. In addition to well described cell-intrinsic roles promoting tumor progression and metastasis, CD155 has now been implicated in immune regulation.
Mark J. Smyth, Jason Madore, Jake S O'Donnell   +2 more
exaly   +6 more sources

CD155 is a putative therapeutic target in medulloblastoma

Clinical and Translational Oncology, 2022
Medulloblastoma is the most common pediatric malignant brain tumor, consisting of four molecular subgroups (WNT, SHH, Group 3, Group 4) and 12 subtypes. Expression of the cell surface poliovirus receptor (PVR), CD155, is necessary for entry of the viral immunotherapeutic agent, PVSRIPO, a polio:rhinovirus chimera.
Sean Li, Roger McLendon, Eric Sankey, Reb Kornahrens, Anne-Marie Lyne, Florence Marie Géraldine Cavalli, Zachary McKay, James Emmett Herndon, Marc Remke, Daniel Picard, Matthias Gromeier, Michael Brown, Eric Michael Thompson   +12 more
openaire   +2 more sources

CD155 in tumor progression and targeted therapy

Cancer Letters, 2022
CD155, also known as the poliovirus receptor (PVR), has received considerable attention in recent years because of its intrinsic and extrinsic roles in tumor progression. Although barely expressed in host cells, CD155 is upregulated in tumor-infiltrating myeloid cells.
Zhan, Meixiao, Zhang, Zhiren, Zhao, Xiaoguang, Zhang, Yuncong, Liu, Tianqing (Michelle) (R20191), Lu, Ligong, Li, Xianyang   +6 more
openaire   +3 more sources

Identification of Secreted CD155 Isoforms

Biochemical and Biophysical Research Communications, 2003
The CD155 gene is a member of the immunoglobulin superfamily. We first demonstrate the existence of soluble CD155 (sCD155) isoforms in culture medium conditioned by CD155-expressing cells, in human serum and in cerebrospinal fluid. sCD155 concentration was measured in human serum and cerebrospinal fluid using a specific ELISA.
Marc Denis, Damien Masson, Hervé Blottière   +2 more
exaly   +3 more sources

CD155 And Its Receptors in Cancer Immune Escape and Immunotherapy

Cancer Letters, 2023
In recent years, there have been multiple breakthroughs in cancer immunotherapy, with immune checkpoint inhibitors becoming the most promising treatment strategy. However, available drugs are not always effective. As an emerging immune checkpoint molecule, CD155 has become an important target for immunotherapy.
Qiwen Wu, Zhaoyang Zeng, Wei Xiong
exaly   +3 more sources

CD155: A Key Receptor Playing Diversified Roles

Current Molecular Medicine, 2022
: Cluster of differentiation (CD155), formerly identified as poliovirus receptor (PVR) and later as immunoglobulin molecule, is involved in cell adhesion, proliferation, invasion and migration. It is a surface protein expressed mostly on normal and transformed malignant cells. The expression of the receptor varies based on the origin of tissue.
Shyam Sundar, Nandi, Trupti, Gohil, Sonali Ankush, Sawant, Upendra Pradeep, Lambe, Sudip, Ghosh, Snehasis, Jana   +5 more
openaire   +2 more sources

Hematopoietic cells from CD155-transgenic mice express CD155 and support poliovirus replication ex vivo

Microbial Pathogenesis, 2000
Despite identification of the poliovirus (PV) receptor (CD155), mechanisms by which this molecule mediates paralytic disease remain obscure. Unanswered questions include CD155 localization in human tissues, the nature of cells supporting the first round of replication, identity of nonneural replication sites, and route of entry into the CNS. In earlier
M S, Freistadt, K E, Eberle
openaire   +2 more sources

CD155 Contributes to the Mesenchymal Phenotype of Triple-Negative Breast Cancer [PDF]

Cancer Science, 2020
AbstractPatients with triple‐negative breast cancer (TNBC) lack molecular targets and have an unfavorable outcome. CD155 is overexpressed in human cancers, but whether it plays a role in TNBC is unexplored. Here we found that CD155 was enriched in both TNBC cell lines and tumor tissues.
Qianqian Zheng, Biao Wang, Chenghai Zhao
exaly   +3 more sources

CD155 as an emerging target in tumor immunotherapy

International Immunopharmacology
CD155 is an immunoglobulin-like protein overexpressed in almost all the tumor cells, which not only promotes proliferation, adhesion, invasion, and migration of tumor cells, but also regulates immune responses by interacting with TIGIT, CD226 or CD96 receptors expressed on several immune cells, thereby modulating the functionality of these cellular ...
Jiang-Wan Wu, Ying Liu, Xing-Jie Dai, Hong-Min Liu, Yi-Chao Zheng, Hui-Min Liu   +5 more
openaire   +2 more sources

CD155/TIGIT, a novel immune checkpoint in human cancers (Review)

Oncology Reports, 2021
CD155/T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a novel type of immune checkpoint. CD155 is an adhesion molecule that is upregulated during tumor progression and promotes the proliferative and migratory abilities of tumor cells via various pathways.
Lu, Liu, Xuewu, You, Sai, Han, Yu, Sun, Junhua, Zhang, Youzhong, Zhang   +5 more
openaire   +2 more sources